More clinical trials are ongoing for monotherapies or combination therapies of mIDH1/2 inhibitors LY3410738 and IDH305 for gliomas and other solid tumors with IDH1/2 mutations (ClinicalTrials.gov). This evidence concerns the gene IDH1 and central nervous system cancer.